Veltassa, developed by Vifor Pharma, is a sodium-free potassium binder approved for the treatment of hyperkalemia. When the cost of therapy is considered, use of Veltassa was associated with about 20% relative reduction in total health care expenditures, which included costs for outpatient, inpatient, and emergency department visits. The potassium-lowering agent Veltassa (patiromer) was associated with a reduction in inpatient and emergency department visits, lowering total overall spending, according to a recent study published in the Journal of Medical Economics.Īmong Medicare Advantage patients with hyperkalemia, or high potassium levels, investigators found that patients taking Veltassa were about 50% less likely to incur inpatient costs greater than or equal to the mean inpatient cost for Medicare Advantage patients ($14,900).
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |